ArticleInternational journal of chronic obstructive pulmonary disease2025
TFR1 as a Biomarker of Pulmonary Fibrosis Development in COPD Patients.
Article in International journal of chronic obstructive pulmonary disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ironing out COPD: ferroptosis-driven immune dysregulation, metabolic rewiring, and precision therapeutic opportunities.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ferroptosis is involved in chronic lung injury, including COPD and pulmonary fibrosis. In this study, we investigated the role of transferrin protein 1 (TFR1), as a ferroptosis marker, in the development of COPD-associated pulmonary fibrosis. Methods: The expression of TFR1 was elevated in 97 patients with COPD. The correlation analysis of the clinical characteristic was performed including the frequency of acute exacerbation, the fibrosis score, etc. and the expression of TFR1. Animal experiments were carried out to verify TFR1 expression in a rat COPD model. Results: The results showed that the expression of TFR1 was related to DLCO%, 6 MWT, GOLD grade, frequency of acute exacerbation and fibrosis score. Together, in the rat COPD model, higher TFR1 was related to a higher lung injury score and a higher lung fibrosis score. Conclusion: In summary, these results indicated that serum TFR1 levels related to the severity of pulmonary fibrosis in clinical practice and may provide a potential target for the treatment of pulmonary fibrosis development from patients with COPD in the future.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.